Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 196

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Peripheral levels of C-reactive protein, tumor necrosis factor-α, interleukin-6, and interleukin-1β across the mood spectrum in bipolar disorder: A meta-analysis of mean differences and variability

Open access
Solmi, Marco, Suresh Sharma, Manu, Osimo, Emanuele F., Fornaro, Michele, Bortolato, Beatrice, Croatto, Giovanni, Miola, Alessandro, Vieta, Eduard, Pariante, Carmine M., Smith, Lee, Fusar-Poli, Paolo, Shin, Jae Il, Berk, Michael, Carvalho, Andre F. · 2021 · Brain, Behavior, and Immunity

Abstract

IMPORTANCE It is unclear whether differences exist in the magnitude and variability of pro-inflammatory mediators in the different phases of bipolar disorder (BD) and among subjects with BD, as compared to healthy controls. OBJECTIVE To run a comparative meta-analysis of C-Reactive Protein (CRP), IL-1, IL-6, TNF-α in BD vs healthy controls, measuring mean and variability effects on all subjects. Sensitivity analyses include disease activity. DATA SOURCES Systematic review of observational studies in PubMed and PsycInfo up to February 2nd, 2020. STUDY SELECTION Case-control studies reporting inflammatory mediators' levels in BD and controls. DATA EXTRACTION AND SYNTHESIS Summary distribution measures of circulating CRP, IL-1β, IL-6, TNF-α in participants with BD and control groups were extracted. Random-effects multivariate meta-analyses were conducted based on individual study/mediator effect sizes (Hedge's g). Main Outcomes and Measures. Co-primary outcomes were inflammatory mediators' levels (Hedge's g) and variability (coefficient of variance ratio (CVR)) differences between participants with BD across the mood spectrum and controls. RESULTS Out of the initial 729 papers, 72 were assessed and then excluded after full-text review, and ultimately 53 studies were included in the systematic review, while 49 were included in the meta-analysis. The mean age was 36.96 (SD: 9.29) years, and the mean female percentage was 56.31 (SD: 16.61). CRP (g=0.70, 95% CI 0.31-1.09, k=37, BD=2,215 vs HC=3,750), IL-6 (g=0.81, 95% CI 0.46-1.16, k=45, BD=1,956 vs HC=4,106), TNF-α (g=0.49, 95% CI 0.19-0.78, k=49, BD=2,231 vs HC=3,017) were elevated in subjects with BD vs HC, but not IL-1β (g=-0.28, 95% CI -0.68-0.12, k=4, BD=87 vs HC=66). When considering euthymic, depressive, and manic episodes separately, CRP and TNF-α were elevated in both depressive and manic episodes, but not in euthymia, while IL-6 remained elevated regardless of the disease state. No difference in CVR emerged for CRP, IL-1β, and TNF-α, while a lower CVR was observed for IL-6. When considering disease phases, CVR was higher in BD than in HCs for CRP during depressive episodes, lower for IL-6 during euthymia, and higher during manic episodes for CRP, IL-6, and TNF-α. Sensitivity analyses after excluding outliers identified with funnel plot visual inspection, low-quality studies, and considering only studies matched per body mass index confirmed the main results. Meta-regression showed that age (IL-6, TNF-α), gender (CRP), duration of illness (CRP) moderated elevated individual inflammatory levels. Conclusions and Relevance Peripheral pro-inflammatory marker elevations were confirmed in BD. CRP and TNF-α could represent state markers, as they were only elevated during mood episodes, while IL-6 appeared to be a trait marker for BD. Increased variability of specific inflammatory mediators in specific disease active states suggests that a subset of subjects with BD may exhibit elevated inflammation as part of a manic or depressive episode.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbi.2021.07.014

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 68

  1. Aas, 2017, Childhood maltreatment severity is associated with elevated C-reactive protein and body mass index in adults with schizophrenia and bipolar diagnoses, Brain. Behav. Immun., 65, 342, 10.1016/j.bbi.2017.06.005 · DOI
  2. Bai, 2015, Comparison of pro-inflammatory cytokines among patients with bipolar disorder and unipolar depression and normal controls, Bipolar Disord., 17, 269, 10.1111/bdi.12259 · DOI
  3. Barbosa, 2013, Altered intracellular signaling cascades in peripheral blood mononuclear cells from BD patients, J. Psychiatr. Res., 47, 1949, 10.1016/j.jpsychires.2013.08.019 · DOI
  4. Barbosa, 2012, Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers, J. Affect. Disord., 137, 151, 10.1016/j.jad.2011.12.034 · DOI
  5. Barbosa, 2012, Increased levels of adipokines in bipolar disorder, J. Psychiatr. Res., 46, 389, 10.1016/j.jpsychires.2011.11.010 · DOI
  6. Barbosa, 2017, Plasma levels of Tumor Necrosis factor superfamily molecules are increased in bipolar disorder, Clin. Psychopharmacol. Neurosci., 15, 269, 10.9758/cpn.2017.15.3.269 · DOI
  7. Bender, 2008, Attention should be given to multiplicity issues in systematic reviews, J. Clin. Epidemiol., 61, 857, 10.1016/j.jclinepi.2008.03.004 · DOI
  8. Berk, 2020, Anti-inflammatory treatment of bipolar depression: promise and disappointment, Lancet Psychiat., 7, 467, 10.1016/S2215-0366(20)30155-3 · DOI
  9. Brugger, 2017, Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia: a Meta-analysis, JAMA Psychiatry, 74, 1104, 10.1001/jamapsychiatry.2017.2663 · DOI · Paper page
  10. Chakrabarty, 2019, Inflammatory cytokines and cognitive functioning in early-stage bipolar I disorder, J. Affect. Disord., 245, 679, 10.1016/j.jad.2018.11.018 · DOI
  11. Civil Arslan, F., Tiryaki, A., Özkorumak Karagüzel, E., Aral, G., Sarıoğlu, O.., İnce, İ., Çankaya, S., Alver, A., n.d. The Relationship of Interleukin-18 and Interleukin-6 Levels with Cognitive Functions in Bipolar Disorder. Turk Psikiyatr. Derg 28(2), 81–88.
  12. Cunha, 2008, Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder, Eur. Arch. Psychiatry Clin. Neurosci., 258, 300, 10.1007/s00406-007-0797-0 · DOI
  13. da Silva, 2017, Peripheral insulin-like growth factor 1 in bipolar disorder, Psychiatry Res., 250, 30, 10.1016/j.psychres.2017.01.061 · DOI
  14. De Berardis, 2008, Evaluation of C-reactive protein and total serum cholesterol in adult patients with bipolar disorder, Int. J. Immunopathol. Pharmacol., 21, 319, 10.1177/039463200802100208 · DOI
  15. Dickerson, 2007, Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder, Prog. Neuro-Psychopharmacology Biol. Psychiatry, 31, 952, 10.1016/j.pnpbp.2007.02.018 · DOI
  16. Doganavsargil-Baysal, 2013, Levels of TNF-α, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder, Hum. Psychopharmacol. Clin. Exp., 28, 160, 10.1002/hup.2301 · DOI
  17. Fernandes, 2020, Editorial: back to the future: on the road towards precision Psychiatry, Front. Psychiatry, 11, 112, 10.3389/fpsyt.2020.00112 · DOI
  18. Fernandes, 2017, The new field of ‘precision psychiatry’, BMC Med., 15, 80, 10.1186/s12916-017-0849-x · DOI · Paper page
  19. Firth, 2019, The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness, The Lancet Psychiatry, 6, 675, 10.1016/S2215-0366(19)30132-4 · DOI · Paper page
  20. Fonseka, 2015, Novel investigational drugs targeting IL-6 signaling for the treatment of depression, Expert Opin. Investig. Drugs, 10.1517/13543784.2014.998334 · DOI
  21. Fusar-Poli, 2018, Semistructured Interview for Bipolar At Risk States (SIBARS), Psychiatry Res., 264, 302, 10.1016/j.psychres.2018.03.074 · DOI
  22. Glaus, 2018, Mood disorders and circulating levels of inflammatory markers in a longitudinal population-based study, Psychol. Med., 48, 961, 10.1017/S0033291717002744 · DOI
  23. He, 2020, Trends in the incidence and DALYs of bipolar disorder at global, regional, and national levels: Results from the global burden of Disease Study 2017, J. Psychiatr. Res., 125, 96, 10.1016/j.jpsychires.2020.03.015 · DOI
  24. Higgins, 2008, Meta-analysis of skewed data: combining results reported on log-transformed or raw scales, Stat. Med., 27, 6072, 10.1002/sim.3427 · DOI · Paper page
  25. Hope, 2015, Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls, Schizophr. Res., 165, 188, 10.1016/j.schres.2015.04.004 · DOI
  26. Hope, 2009, Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor, Bipolar Disord., 11, 726, 10.1111/j.1399-5618.2009.00757.x · DOI
  27. Hornig, 1998, Positive and negative acute phase proteins in affective subtypes, J. Affect. Disord., 49, 9, 10.1016/S0165-0327(97)00180-8 · DOI
  28. Hung, 2007, Insulin sensitivity, proinflammatory markers and adiponectin in young males with different subtypes of depressive disorder, Clin. Endocrinol. (Oxf), 67, 784, 10.1111/j.1365-2265.2007.02963.x · DOI
  29. Jacoby, 2016, Cytokines, brain-derived neurotrophic factor and C-reactive protein in bipolar i disorder - results from a prospective study, J. Affect. Disord., 197, 167, 10.1016/j.jad.2016.03.040 · DOI
  30. Kapczinski, 2011, Peripheral biomarkers and illness activity in bipolar disorder, J. Psychiatr. Res., 45, 156, 10.1016/j.jpsychires.2010.05.015 · DOI · Paper page
  31. Karabulut, 2019, Inflammation and neurodegeneration in patients with early-stage and chronic bipolar disorder, Turkish J. Psychiatry, 30
  32. Kauer-Sant'Anna, 2009, Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder, Int. J. Neuropsychopharmacol., 12, 447, 10.1017/S1461145708009310 · DOI · Paper page
  33. Kessing, 2015, Causes of decreased life expectancy over the life span in bipolar disorder, J. Affect. Disord., 180, 142, 10.1016/j.jad.2015.03.027 · DOI · Paper page
  34. King, 2019, Inflammation, glutamate, and cognition in bipolar disorder type II: a proof of concept study, Front. Psychiatry, 10, 10.3389/fpsyt.2019.00066 · DOI
  35. Koga, 2019, Altered polyunsaturated fatty acid levels in relation to proinflammatory cytokines, fatty acid desaturase genotype, and diet in bipolar disorder, Transl. Psychiatry, 9, 208, 10.1038/s41398-019-0536-0 · DOI
  36. Lesh, 2018, Cytokine alterations in first-episode schizophrenia and bipolar disorder: relationships to brain structure and symptoms, J. Neuroinflammation, 15, 10.1186/s12974-018-1197-2 · DOI
  37. Maes, 2014, Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?, Expert Opin. Ther. Targets, 18, 495, 10.1517/14728222.2014.888417 · DOI · Paper page
  38. Manchia, 2020, Translating big data to better treatment in bipolar disorder - a manifesto for coordinated action, Eur. Neuropsychopharmacol., 36, 121, 10.1016/j.euroneuro.2020.05.006 · DOI
  39. Mao, 2018, Different levels of pro- and anti-inflammatory cytokines in patients with unipolar and bipolar depression, J. Affect. Disord., 237, 65, 10.1016/j.jad.2018.04.115 · DOI · Paper page
  40. McIntyre, 2019, Efficacy of Adjunctive Infliximab vs Placebo in the treatment of adults with Bipolar I/II depression: a randomized clinical trial, JAMA psychiatry, 76, 783, 10.1001/jamapsychiatry.2019.0779 · DOI · Paper page
  41. Milaneschi, 2020, Depression heterogeneity and its biological underpinnings: toward immunometabolic depression, Biol. Psychiatry, 88, 369, 10.1016/j.biopsych.2020.01.014 · DOI · Paper page
  42. Mizuno, 2016, Clinical and biological correlates of resilience in patients with schizophrenia and bipolar disorder: a cross-sectional study, Schizophr. Res., 175, 148, 10.1016/j.schres.2016.04.047 · DOI
  43. Modabbernia, 2013, Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies, Biol. Psychiatry, 74, 15, 10.1016/j.biopsych.2013.01.007 · DOI · Paper page
  44. Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, J. Clin. Epidemiol., 62, 1006, 10.1016/j.jclinepi.2009.06.005 · DOI · Paper page
  45. Mondin, 2016, Circadian preferences, oxidative stress and inflammatory cytokines in bipolar disorder: a community study, J. Neuroimmunol., 301, 23, 10.1016/j.jneuroim.2016.10.012 · DOI
  46. Mora, 2019, High BDNF serum levels are associated to good cognitive functioning in bipolar disorder, Eur. Psychiatry, 60, 97, 10.1016/j.eurpsy.2019.02.006 · DOI
  47. Morris, 2019, Shared pathways for neuroprogression and somatoprogression in neuropsychiatric disorders, Neurosci. Biobehav. Rev., 107, 862, 10.1016/j.neubiorev.2019.09.025 · DOI
  48. Munkholm, 2015, Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients, Brain. Behav. Immun., 43, 205, 10.1016/j.bbi.2014.09.021 · DOI
  49. Ortiz-Domínguez, 2007, Immune variations in bipolar disorder: phasic differences, Bipolar Disord., 9, 596, 10.1111/j.1399-5618.2007.00493.x · DOI · Paper page
  50. Pan, 2020, Excess mortality and shortened life expectancy in people with major mental illnesses in Taiwan, Epidemiol. Psychiatr. Sci., 29, 10.1017/S2045796020000694 · DOI
  51. Pandey, 2015, Abnormal gene expression of proinflammatory cytokines and their receptors in the lymphocytes of patients with bipolar disorder, Bipolar Disord., 17, 636, 10.1111/bdi.12320 · DOI
  52. Pantović-Stefanović, 2018, sVCAM-1, sICAM-1, TNF-α and IL-6 levels in bipolar disorder type I: acute, longitudinal and therapeutic implications, World J. Biol. Psychiatry, 19, S41, 10.1080/15622975.2016.1259498 · DOI
  53. Quidé, 2019, Association between childhood trauma exposure and pro-inflammatory cytokines in schizophrenia and bipolar-I disorder, Psychol. Med., 49, 2736, 10.1017/S0033291718003690 · DOI
  54. Remlinger-Molenda, 2012, Activity of selected cytokines in bipolar patients during manic and depressive episodes, Psychiatr. Pol., 46, 599
  55. Sanjay, 2017, Plasma interleukin-6 in remitted early bipolar I disorder and subjects at high-risk for bipolar disorder, Asian J. Psychiatr., 10.1016/j.ajp.2017.03.014 · DOI
  56. Sayana, 2017, A systematic review of evidence for the role of inflammatory biomarkers in bipolar patients, J. Psychiatr. Res., 92, 160, 10.1016/j.jpsychires.2017.03.018 · DOI · Paper page
  57. Scola, 2016, Lipid peroxidation biomarkers in adolescents with or at high-risk for bipolar disorder, J. Affect. Disord., 192, 176, 10.1016/j.jad.2015.12.020 · DOI
  58. Stroup, 2000, MOOSE guidelines for meta-analyses and systematic reviews of observational studies, JAMA
  59. Tsai, 2012, Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder, J. Affect. Disord., 136, 110, 10.1016/j.jad.2011.08.022 · DOI
  60. Tunç, 2019, Serum ceruloplasmin-ferroxidase activity in bipolar disorder is elevated compared to major depressive disorder and schizophrenia: a controlled study, Psychiatry Clin. Psychopharmacol., 29, 307, 10.1080/24750573.2019.1584489 · DOI
  61. van den Ameele, 2018, Markers of inflammation and monoamine metabolism indicate accelerated aging in bipolar disorder, Front. Psychiatry, 9, 10.3389/fpsyt.2018.00250 · DOI
  62. Vasconcelos-Moreno, 2017, Telomere length, oxidative stress, inflammation and BDNF levels in siblings of patients with bipolar disorder: implications for accelerated cellular aging, Int. J. Neuropsychopharmacol., 20, 445, 10.1093/ijnp/pyx001 · DOI
  63. Vieta, 2015, Personalized medicine applied to mental health: precision psychiatry, Rev. Psiquiatr. y Salud Ment. (English Ed.), 8, 117
  64. Wadee, 2002, Serological observations in patients suffering from acute manic episodes, Hum. Psychopharmacol., 17, 175, 10.1002/hup.390 · DOI
  65. Wang, 2016, The differential levels of inflammatory cytokines and bdnf among bipolar spectrum disorders, Int. J. Neuropsychopharmacol., 19, 1, 10.1093/ijnp/pyw012 · DOI
  66. Wieck, 2014, Pro-inflammatory cytokines and soluble receptors in response to acute psychosocial stress: differential reactivity in bipolar disorder, Neurosci. Lett., 10.1016/j.neulet.2014.07.040 · DOI
  67. Wiener, 2017, Inflammatory cytokines and functional impairment in drug-free subjects with mood disorder, J. Neuroimmunol., 307, 33, 10.1016/j.jneuroim.2017.03.003 · DOI
  68. Wu, 2017, Circulating T lymphocyte subsets, cytokines, and immune checkpoint inhibitors in patients with bipolar II or major depression: A preliminary study, Sci. Rep., 7

Cited by

See all 196

Metadata

Authors
Solmi, M., Suresh Sharma, M., Osimo, E. F., Fornaro, M., Bortolato, B., Croatto, G., Miola, A., Vieta, E., Pariante, C. M., Smith, L., Fusar-Poli, P., Shin, J. I., Berk, M., & Carvalho, A. F.
Venue
Brain, Behavior, and Immunity
Publisher
Elsevier BV
Published
2021-10
Volume
97
Pages
193-203
ISSN
0889-1591 (ISSN-L)
OpenAlex
W3186181241
Cited by
196
References
30
FWCI
6.74
Type
journal article
Language
en
Open access
green
Funders
National Health and Medical Research Council (1156072)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Peripheral levels of C-reactive protein, tumor necrosis factor-α, interleukin-6, and interleukin-1β across the mood spectrum in bipolar disorder: A meta-analysis of mean differences and variability. https://app.cochat.ai/papers/10.1016/j.bbi.2021.07.014
The paper
Solmi, M., Suresh Sharma, M., Osimo, E. F., Fornaro, M., Bortolato, B., Croatto, G., Miola, A., Vieta, E., Pariante, C. M., Smith, L., Fusar-Poli, P., Shin, J. I., Berk, M., & Carvalho, A. F. (2021). Peripheral levels of C-reactive protein, tumor necrosis factor-α, interleukin-6, and interleukin-1β across the mood spectrum in bipolar disorder: A meta-analysis of mean differences and variability. Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2021.07.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.